Anúncio
Anúncio

NPCE

NPCE logo

Neuropace, Inc. Common Stock

16.75
USD
Patrocinado
-0.21
-1.24%
09 de jan., 15:59 UTC -5
Encerrado
exchange

Pós-Mercado

16.95

+0.20
+1.16%

Relatórios de Lucros NPCE

Rácio de surpresa positiva

NPCE separação 12 de 19 últimas estimativas.

63%

Próximo Relatório

Data do Próximo Relatório
02 de mar. de 2026
Estimate for Q4 25 (Revenue/ EPS)
$24.92M
/
-$0.18
Mudanças implicadas de Q3 25 (Revenue/ EPS)
-8.90%
/
+63.64%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
+16.08%
/
--

Neuropace, Inc. Common Stock earnings per share and revenue

On 04 de nov. de 2025, NPCE reported earnings of -0.11 USD per share (EPS) for Q3 25, beating the estimate of -0.20 USD, resulting in a 45.05% surprise. Revenue reached 27.35 milhão, compared to an expected 25.13 milhão, with a 8.86% difference. The market reacted with a +38.09% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 10 analistas forecast an EPS of -0.18 USD, with revenue projected to reach 24.92 milhão USD, implying an aumentar of 63.64% EPS, and diminuir of -8.90% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
AngioDynamics, Inc.
Report Date
06 de jan. de 2026 Para Q2 26
Estimativa
-$0.10
Real
$0.00
Surpresa
+100.00%
FAQ
For Q3 2025, Neuropace, Inc. Common Stock reported EPS of -$0.11, beating estimates by 45.05%, and revenue of $27.35M, 8.86% above expectations.
The stock price moved up 38.09%, changed from $9.40 before the earnings release to $12.98 the day after.
The next earning report is scheduled for 02 de mar. de 2026.
Based on 10 analistas, Neuropace, Inc. Common Stock is expected to report EPS of -$0.18 and revenue of $24.92M for Q4 2025.
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio